ArticleJCO precision oncology2022
Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent Disease Is Key.
Evan Rosenbaum et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it